Latest & greatest articles for methylphenidate

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on methylphenidate or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on methylphenidate and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for methylphenidate

41. A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents

A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents A systematic review and economic model (...) of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents King S, Griffin S, Hodges Z, Weatherly H, Asseburg C, Richardson G, Golder S, Taylor E, Drummond M, Riemsma R CRD summary This review concluded that drug treatment was more effective than no drug treatment, but there was insufficient evidence to compare different drugs for effectiveness or safety. This was a well-conducted review

DARE.2006

42. Cognitive effects of immediate-release methylphenidate in children with attention-deficit/hyperactivity disorder

Cognitive effects of immediate-release methylphenidate in children with attention-deficit/hyperactivity disorder Cognitive effects of immediate-release methylphenidate in children with attention-deficit/hyperactivity disorder Cognitive effects of immediate-release methylphenidate in children with attention-deficit/hyperactivity disorder Pietrzak R H, Mollica C M, Maruff P, Snyder P J CRD summary This review assessed the cognitive effects of immediate-release methylphenidate in children (...) with attention-deficit/hyperactivity disorder. The authors conclude that variability in outcomes across studies may be explained by a number of clinical and methodological factors. The review has several methodological weaknesses and it is unclear whether the results of the included studies and their subsequent synthesis can be relied upon. Authors' objectives To evaluate the nature, magnitude and types of cognitive effects of immediate-release methylphenidate in children with attention-deficit/hyperactivity disorder (ADHD). Searching

DARE.2006

43. Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents: review of Technology Appraisal 13

Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents: review of Technology Appraisal 13 Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents: review of Technology Appraisal 13 Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents: review of Technology Appraisal 13 National (...) Institute for Health and Clinical Excellence Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation National Institute for Health and Clinical Excellence. Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents: review of Technology Appraisal 13. London: National Institute for Health and Clinical Excellence

Health Technology Assessment (HTA) Database.2006

44. Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents (TA98)

Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents (TA98) Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents | Guidance and guidelines | NICE Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents Technology appraisal guidance [TA98] Published date: 22 March 2006 Share

National Institute for Health and Clinical Excellence - Technology Appraisals2006

45. A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents

A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents A systematic review and economic model (...) of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents King S, Griffin S, Hodges Z, Weatherly H, Asseburg C, Richardson G, Golder S, Taylor E, Drummond M, Riemsma R Citation King S, Griffin S, Hodges Z, Weatherly H, Asseburg C, Richardson G, Golder S, Taylor E, Drummond M, Riemsma R. A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate

Health Technology Assessment (HTA) Database.2006

47. Cost-effectiveness of dexamphetamine and methylphenidate for the treatment of childhood attention deficit hyperactivity disorder

Cost-effectiveness of dexamphetamine and methylphenidate for the treatment of childhood attention deficit hyperactivity disorder Cost-effectiveness of dexamphetamine and methylphenidate for the treatment of childhood attention deficit hyperactivity disorder Cost-effectiveness of dexamphetamine and methylphenidate for the treatment of childhood attention deficit hyperactivity disorder Donnelly M, Haby M M, Carter R, Andrews G, Vos T Record Status This is a critical abstract of an economic (...) evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of dexamphetamine (DEX) and methylphenidate (MPH) to treat childhood attention deficit hyperactivity disorder (ADHD). The two treatment protocols were accurately described. The drug dosages were as follows. During the titration period (4

NHS Economic Evaluation Database.2004

48. Cost-effectiveness of methylphenidate versus AMP/DEX mixed slats for the first-line treatment of ADHD

Cost-effectiveness of methylphenidate versus AMP/DEX mixed slats for the first-line treatment of ADHD Cost-effectiveness of methylphenidate versus AMP/DEX mixed slats for the first-line treatment of ADHD Cost-effectiveness of methylphenidate versus AMP/DEX mixed slats for the first-line treatment of ADHD Narayan S, Hay J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods (...) , the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of methylphenidate (MPH) versus amphetamine/dextroamphetamine mixed salts (AMP/DEX) as first-line agents for the treatment of attention deficit hyperactivity disorder (ADHD) was studied. Type of intervention Treatment. Economic study type Cost-utility analysis. Study population The study population comprised a hypothetical cohort of male children aged

NHS Economic Evaluation Database.2004

49. Methylin (Methylphenidate Hydrochloride) Chewable Tablet

Methylin (Methylphenidate Hydrochloride) Chewable Tablet Drug Approval Package: Methylin (Methylphenidate Hydrochloride) NDA #021475 Drug Approval Package U.S. Food & Drug Administration Enter Search terms Drug Approval Package - Methylin (Methylphenidate Hydrochloride) Chewable Tablet Company: Mallinckrodt, Inc. Application No.: 021475 Approval Date: 04/15/2003 (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) Date created: July 252006 Note: Documents in PDF format require the . - - Links on this page: Note

FDA - Drug Approval Package2003

51. Ritalin LA (Methylphenidate Hydrochloride) Extended-Release Capsules

Ritalin LA (Methylphenidate Hydrochloride) Extended-Release Capsules Drug Approval Package: Ritalin LA (Methylphenidate Hydrochloride) NDA #21-284 Drug Approval Package U.S. Food & Drug Administration Enter Search terms Drug Approval Package - Ritalin LA (Methylphenidate Hydrochloride) Extended-Release Capsules Company: Novartis Pharmaceuticals Corporation Application No.: 21-284 Approval Date: 6/5/2002 (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) Date created: May 13, 2005 Note

FDA - Drug Approval Package2002

52. How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents: a meta-analysis

How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents: a meta-analysis How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents: a meta-analysis How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents: a meta-analysis Schachter H M, Pham B, King J, Langford S, Moher (...) D Authors' objectives To review the efficacy and safety of short-acting methylphenidate (Ritalin), compared with placebo, for attention-deficit disorder (ADD) in individuals aged 18 years and less. Searching The following sources were searched for a range of dates, the earliest being 1981: MEDLINE, EMBASE, PsycINFO, ERIC, CINAHL, HealthSTAR, Biological Abstracts, Current Contents, and Dissertation Abstracts. There were no restrictions on either the language or publication status of the reports

DARE.2001

53. Methylphenidate in children with hyperactivity: review and cost-utility analysis

Methylphenidate in children with hyperactivity: review and cost-utility analysis Methylphenidate in children with hyperactivity: review and cost-utility analysis Methylphenidate in children with hyperactivity: review and cost-utility analysis Gilmore A, Milne R Authors' objectives To examine the effectiveness and cost-effectiveness of methylphenidate in children with hyperkinetic disorder. Searching The following sources were searched: MEDLINE (from 1966 to 1997), EMBASE (from 1980 to 1997 (...) ), the Social Sciences Citation Index (from 1981 to 1997), the Science Citation Index (from 1981 to 1997), the British Education Index (from 1976 to 1997), the Cochrane Controlled Trials Register and PsycLIT (from 1974 to 1997). Major journals published around the time of the review were searched for additional studies that were not yet listed on the databases. Unpublished material was sought by contacting Portsmouth Hospital's information service, the manufacturers of methylphenidate and the ADD/ADHD

DARE.2001

54. Methylphenidate in children with hyperactivity: review and cost-utility analysis

Methylphenidate in children with hyperactivity: review and cost-utility analysis Methylphenidate in children with hyperactivity: review and cost-utility analysis Methylphenidate in children with hyperactivity: review and cost-utility analysis Gilmore A, Milne R Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical (...) assessment on the reliability of the study and the conclusions drawn. Health technology The use of methylphenidate for the treatment of children with hyperkinetic disorders, as defined using the ICD-10 criteria. Type of intervention Treatment. Economic study type Cost-utility analysis. Study population The study population comprised children aged 6 to 12 years of age, presenting with hyperkinetic disorders. The disease definition was based on the ICD-10 criteria. These stated that all three features

NHS Economic Evaluation Database.2001

55. Methylphenidate (Ritalin, Equasym) for attention deficit/hyperactivity disorder (ADHD) in childhood

Methylphenidate (Ritalin, Equasym) for attention deficit/hyperactivity disorder (ADHD) in childhood Methylphenidate (Ritalin, Equasym) for attention deficit/hyperactivity disorder (ADHD) in childhood Methylphenidate (Ritalin, Equasym) for attention deficit/hyperactivity disorder (ADHD) in childhood National Institute for Clinical Excellence Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made (...) for the HTA database. Citation National Institute for Clinical Excellence. Methylphenidate (Ritalin, Equasym) for attention deficit/hyperactivity disorder (ADHD) in childhood. London: National Institute for Clinical Excellence (NICE). Technology Appraisal Guidance 13. 2000 Authors' objectives To provide guidance on the use of methylphenidate (Ritalin, Equasym) for attention deficit/hyperactivity disorder (ADHD) in childhood. Authors' conclusions Guidance 1.1 Methylphenidate is recommended for use as part

Health Technology Assessment (HTA) Database.2000

56. Methylphenidate in children with hyperactivity

Methylphenidate in children with hyperactivity Methylphenidate in children with hyperactivity Methylphenidate in children with hyperactivity Gilmore A, Best L, Milne R Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Gilmore A, Best L, Milne R. Methylphenidate in children with hyperactivity. Southampton: Wessex Institute for Health (...) Research and Development (WIHRD) 1998 Authors' objectives Methylphenidate has been used widely in hyperactive children since the 1970s. Its use has become commonplace in the UK over the last few years and is rising rapidly. The authors evaluate its effectiveness in the treatment of children with hyperkinetic disorder. Authors' conclusions As evidence from good and medium quality RCTs shows benefits of methylphenidate over weeks and months respectively, and methylphenidate is of reasonable cost

Health Technology Assessment (HTA) Database.1998